What treatment would you recommend for a patient with early-stage TNBC treated per KEYNOTE-522, PD-L1 CPS >10, with metastatic recurrence within 12 months of treatment completion?

Is there a duration of time during which you would not re-challenge with immunotherapy?

Answer from: Medical Oncologist at Academic Institution

In the absence of a clinical trial option for this patient with triple-negative breast cancer (TNBC) who had completed the KEYNOTE-522 regimen <12 months ago for non-metastatic TNBC and who now has metastatic TNBC which tested PD-L1 positive (PD-L1 CPS >10), I would offer immunotherapy with pe...

Comments

Medical Oncologist at NYU Langone Medical Center
Regulatory issues aside, would pembrolizumab + sac...

Medical Oncologist at Cancer Treatmt Center of America
Although not yet approved, I would use data from t...

Medical Oncologist at NYU Winthrop Hospital
Agree with sacituzumab and pembrolizumab.

Medical Oncologist at Breastlink Medical Group
Also in favor of saci and pembro + biopsy and sequ...

Medical Oncologist at St Lukes Cancer Care Assocs
I would go straight to ADC. I won’t add CPI ...

Medical Oncologist at Millennium Physicians
Agree with the above, either use saci alone or wit...

Please select the option that best describes you:

What treatment would you recommend for a patient with early-stage TNBC treated per KEYNOTE-522, PD-L1 CPS >10, with metastatic recurrence within 12 months of treatment completion?

Related Questions